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ABSTRACT
Aims/Introduction: Pharmacological levels of glucagon-like peptide-1 (GLP-1) can
decelerate gastric emptying (GE) and reduce postprandial glucose levels. Most previous
studies have used liquid meals to evaluate GE. We evaluated the effects of GLP-1 receptor
agonists (GLP-1 RAs) on GE and postprandial glucose excursion in Japanese type 2 dia-
betes mellitus patients using a combination of solid and liquid meals.
Materials and Methods: In this single-center, prospective, open-label study, nine
healthy individuals and 17 patients with type 2 diabetes mellitus consumed a 460-kcal
combination of a solid and liquid meal labeled with 13C-acetic acid. GE was measured
from t = 0 to 150 min in a continuous 13C breath test. Eight participants with type 2 dia-
betes mellitus were administered GLP-1 RAs, and we examined the relationship between
GE and blood glucose excursion.
Results: There were no differences in the average GE coefficient (GEC) and lag time
between the healthy and type 2 diabetes mellitus groups. However, the type 2 diabetes melli-
tus group showed larger GEC variations (P < 0.05). The coefficient of variation of R-R intervals
was a significant predictor of GEC in type 2 diabetes mellitus patients (P < 0.01). The short-act-
ing GLP-1 RA reduced the GEC at 1 month (P = 0.012), whereas the long-acting GLP-1 RA did
not significantly change the GEC after treatment. A positive relationship was observed between
postprandial glucose excursion from T0 min to T60 min and the GEC (r
2 = 0.75; P < 0.01).
Conclusions: The reduction in GE rate by the administration of GLP-1 RAs can predict
the improvement in postprandial glucose excursion in type 2 diabetes mellitus patients.
INTRODUCTION
Type 2 diabetes mellitus is characterized by progressive hyper-
glycemia, and a high risk of microvascular and macrovascular
complications. The maintenance of strict glycemic control is
required for the prevention of complications. Postprandial hyper-
glycemia, particularly, is an independent cardiovascular risk fac-
tor1,2.
Postprandial glucose is controlled by numerous factors, includ-
ing gastric emptying (GE), intestinal carbohydrate digestion and
absorption, and postprandial insulin secretion. GE is a major fac-
tor in the determination of postprandial glucose levels in healthy
people, as well as those with diabetes, and accounts for ~35% of
the variance in the initial glycemic response to oral carbohy-
drates3,4. After bariatric surgery, meal ingestion results in earlier
and higher glucose peaks. This pattern is attributed to the more
rapid transit of nutrients into the small intestine from the
restricted gastric compartments inherent to such types of surgery5.Received 10 January 2019; revised 8 May 2019; accepted 7 July 2019
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GE can be measured by a number of methods, including
direct techniques, such as scintigraphy, and indirect techniques
such as the quantification of 13C and plasma acetaminophen6.
Indirect methods depend on the speed of delivery of the sub-
strate into the duodenum as a rate-limiting step for absorp-
tion and metabolism. 13C acetic or octanoic acid breath tests
are well correlated to scintigraphy – the gold standard for GE
measurement7 and are non-invasive, quantitative and less
expensive than scintigraphy6. They are reproducible and have
been validated in a cohort of diabetes patients, with a
reported sensitivity and specificity of 75–86% and 80–86%,
respectively, in the detection of delayed GE8,9. However, most
previous studies reporting on GE used nutrient-containing liq-
uid meals or low-caloric solid foods (200–255 kcal)10–12. The
liquid or solid meal portions were small, compared with daily
meals. Additionally, there is little evidence on the relationship
between solid and liquid meals in terms of GE in type 2 dia-
betes mellitus patients3,10,13. The intragastric distribution of
solid and liquid meal components is different, with increased
retention of solid and liquid in the proximal stomach, and
increased retention of solid, but not liquid, in the distal stom-
ach. In solid meals, GE involves the storage of food, mixing
with gastric secretions, grinding of solid food into particles
sized 1–2 mm in diameter, and the subsequent delivery into
the small intestine at a rate designed to optimize digestion
and absorption14.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
released predominantly from the small intestine in response
to food intake, which reduces postprandial glucose levels by
enhancing the rate of glucose-dependent insulin secretion.
Additionally, the administration of pharmacological levels of
GLP-1 decelerates GE, which is associated with the relaxation
of the proximal stomach, inhibition of antral and duodenal
motility, and stimulation of pyloric pressure15. Furthermore,
postprandial glucose level reductions, induced by intravenous
GLP-1 administration, are closely related to the magnitude of
GE reductions in healthy people4,16,17. GLP-1 receptor ago-
nists (GLP-1 RAs), classified as “short”- and “long”-acting by
the duration of action, are important in the deceleration of
GE, besides stimulatory insulin secretion18. In previous
reports, short-acting GLP-1 RAs slowed GE and reduced
postprandial glucose excursions (PPGE) in a 13C octanoic
acid breath test19,20. Whether there is a difference in GE and
glucose excursion between short-acting and long-acting GLP-1
RAs is unclear.
GE is important for determining postprandial glucose levels.
However, limited studies have been carried out to evaluate GE
after GLP-1 RA treatment using solid meals. It remains unclear
how GLP-1 RA can affect the interaction between GE and
blood glucose excursion in Japanese patients with type 2 dia-
betes mellitus. The present study aimed to evaluate GE rates by
combined meals of solid and liquid, and compare the effects of




Healthy controls and participants with type 2 diabetes mellitus,
aged ≥20 years, were recruited for the investigation of GE,
between April 2014 and January 2017. This was a prospective,
open-label study carried out in Akita University Hospital, Akita,
Japan. At screening, participants with type 1 diabetes, gastroin-
testinal tract diseases including gastroparesis, history of gas-
trointestinal surgery, cardiac disease, pulmonary disease,
pancreatic disease, liver disease, renal disease, alcohol or drug
abuse, malignancy and pregnancy were excluded. Additionally,
participants taking medications known to affect gastrointestinal
motility or appetite, or who smoked >10 cigarettes per day
were excluded. Type 2 diabetes mellitus was diagnosed accord-
ing to the Japanese Diabetes Society criteria21. First, we exam-
ined GE between healthy controls and type 2 diabetes mellitus
patients. Second, we evaluated the relationship between GE and
PPGE. GLP-1 RAs were administered to eight type 2 diabetes
mellitus patients. Their glycated hemoglobin (HbA1c) values
were >7%. We selected individuals with stable retinopathy and
until the appearance of macroalbuminuria, and obtained
informed consent to administer GLP-1 RAs. Drug-naive
patients were excluded. Lixisenatide, exenatide and liraglutide
were approved for use in Japan at the time of this study. We
administered lixisenatide at 20 lg, liraglutide at 0.9 mg once
daily and exenatide at 10 lg twice daily.
Meal test
Participants underwent a morning meal test after an overnight
fast. The test meal comprised creamed chicken, crackers and
pudding (total energy 460 kcal, carbohydrate 56.5 g, protein
18.0 g, fat 18.0 g). The creamed chicken contained 100 mg of
13C-acetic acid (Cambridge Isotope Laboratories, Inc, Tewks-
bury, MA, USA). Participants took turns to ingest the creamed
chicken and crackers first, and then the pudding. Then, they
drank 100 mL of water. Time 0 was considered to be the
beginning of the breakfast, which was consumed within
15 min. To analyze the GE rate, a standardized 13C acetic acid
breath test was carried out. Breath samples were continuously
collected through a nasal tube, and the 13CO2/
12CO2 ratio was
measured using the BreathID system (Exalenz Bioscience Ltd,
Modiin, Israel) up to 150 min after the ingestion of the test
meal. The rationale underlying the breath test methodology
was that, as a result of GE, as 13C acetic acid is rapidly
absorbed and transported to the liver where it is oxidized, the
13CO2/
12CO2 ratio over time provides a measure of GE. GE
was evaluated at baseline, and after 1 week and 1 month of the
administration of GLP-1 RAs. To measure the levels of plasma
glucose and serum C-peptide, blood samples were collected at
T = 0, 30, 60, 120 and 180 min after test meal ingestion.
Data analysis of the 13C-acetic acid breath test
The 3CO2/
12CO2 ratio values were expressed as percentage
doses per hour of 13C recovered (PDR) over time for each time
390 J Diabetes Investig Vol. 11 No. 2 March 2020 ª 2019 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
O R I G I N A L A R T I C L E
Suganuma et al. http://wileyonlinelibrary.com/journal/jdi
interval, and as cumulative values over 150 min (CPDR). Based
on the method reported by Ghoos et al.7, the PDR was fitted
to the formula: y (t) = atbe-ct by non-linear regression analysis,
where ‘y’ stands for the percentage of 13C excretion in the
breath per hour, ‘t’ is time in hours, and ‘a’, ‘b’ and ‘c’ are con-
stants. The GE coefficient (GEC) was calculated by ln (a).
These parameters were analyzed using Oridion Research Soft-
ware, b version (Oridion Medical Ltd., Modiin, Israel). GEC
indicates the inclination of pulmonary 13CO2 excretion in the
early phase. A faster (slower) emptying corresponds to a larger
(smaller) GEC. The time to linearly increased 13C excretion
commencement was estimated as the lag time from the CPDR.
For solid meals, digestion has been shown to have a lag phase
representative of the milling function, followed by linear empty-
ing of gastric contents. This period of minimal or absent emp-
tying was defined as the lag time22.
Safety evaluation
Safety and tolerability assessments were carried out based on
adverse events, including symptomatic hypoglycemia (defined
as an event with clinical symptoms that were considered to
result from hypoglycemia), abdominal discomfort, laboratory
data (standard hematology, clinical chemistry and urinalysis
parameters) and local tolerability at the site of injection.
Statistical analysis
Continuous variables are expressed as the mean – standard
deviation or median (range), as appropriate. The primary out-
come was the GE rate with administration of GLP-1 RAs. The
significance of the differences in the values was investigated by
a Mann-Whitney U-test. Stepwise multiple linear regression
was used to determine the predictors of the GEC. A Pearson’s
correlation test was used to determine the relationships between
the changes in the blood glucose levels from T0 min to T60 min
(DBG60–0 min) and several parameters. Glycemic excursion and
GE after the administration of GLP-1 RAs were analyzed using
one-way analysis of variance (ANOVA) for repeated measures
(the Bonferroni correction method was used for the post-hoc
analysis). In the present study, for a 90% chance of a reduction
in GEC of approximately 1 at a level of 0.025, the power calcu-
lations indicated that each of the two groups required at least
four patients.
All statistical analyses of recorded data were carried out using
the Excel statistical software package (BellCurve for Excel; Social
Survey Research Information Co., Ltd., Tokyo, Japan). A P-
value <0.05 was considered to show significant differences.
Ethics
The protocol for this research project was approved by a suit-
ably constituted ethics committee of the institution, and it con-
forms to the provisions of the Declaration of Helsinki.
Committee of Akita University Graduate School of Medicine,
Approval No. 1160. Written informed consent was obtained
from all study participants.
RESULTS
GE in type 2 diabetes mellitus
GE was evaluated in a total of nine healthy controls and 17
type 2 diabetes mellitus patients (Table 1). Figure 1a and b
shows the CPDR and PDR during 150 min in both the healthy
Table 1 | Characteristics of the participants with type 2 diabetes and healthy controls
Healthy control participants Type 2 diabetes patients
n (male/female) 9 (7/2) 17 (9/8)
Age (years) 36.5 – 7.4 63.1 – 15.2
BMI (kg/m2) 22.6 – 2.8 26.9 – 5.59
Duration of diabetes (years) – 16.9 – 12.9
Fasting plasma glucose (mg/dL) 88 – 8.8 134.9 – 29.5
HbA1c (%) 5.2 – 0.42 8.96 – 1.24
HOMA-R/HOMA-b 1.0 – 0.35/63.5 – 16.1 –
CPI/SUIT – 1.65 – 0.89/39.0 – 24.1
Hypertension (n)/dyslipidemia (n) 0/0 12/12




Nephropathy: none – 10
Microalbuminuria 5
Macroalbuminuria 2
Neuropathy: peripheral – 14
Autonomic 3
Data are presented the mean – standard deviation. BMI, body mass index; SUIT, secretory units of islets in transplantation; CPI, C-peptide
immunoreactivity index; HbA1c, glycated hemoglobin; HOMA-b, homeostasis model assessment of b-cell function; HOMA-R, homeostasis model
assessment of insulin resistance.
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controls and type 2 diabetes mellitus patients after consumption
of a meal with 13C-labeled acetic acid. The average lag time
was not different between the two groups (healthy controls:
9.82 – 3.21 min, type 2 diabetes mellitus: 10.9 – 5.76 min,
P = 0.73). Variations in lag time tended to be larger in the
type 2 diabetes mellitus group (P = 0.09). Peak 13CO2 excretion
occurred at 63.8 – 22.7 min in healthy controls, and
71.9 – 36.4 min in the type 2 diabetes mellitus group
(P = 0.98). The GEC, the breath test parameter, was
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Figure 1 | 13CO2 excretion curves after the administration of a meal labeled with
13C acetic acid, lag time and the gastric emptying coefficient
(GEC) of the gastric emptying values in healthy control participants and type 2 diabetes mellitus patients. (a) Cumulative percentage dose (CPDR)
and lag time. (b) Percentage dose per hour of 13C recovered (PDR) and the GEC. (c,d) Blood glucose profile. S-CPR, serum C-peptide.
[Correction added on 6 August, after first online publication: Figure 1b has been amended.]
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diabetes mellitus group. There were no significant differences in
the average GEC between the two groups (P = 0.40), whereas
variations in the GEC were significantly larger in the type 2
diabetes mellitus group (P = 0.033).
Stepwise multiple linear regression was used to predict the
GEC based on age, duration, body mass index, fasting plasma
glucose, urinary C-peptide, C-peptide index, secretory units of
islets in transplantation (SUIT), HbA1c and the electrocardio-
gram R-R interval variation coefficient (CVR-R)23. Only CVR-
R was a significant predictor of the GEC (P < 0.01). A signifi-
cant regression equation was observed (F(1,15) = 11.1454,
P = 0.0049), with an r2 of 0.4432 (Table 2). The type 2 dia-
betes mellitus patients’ predicted GEC was equal to
2.2706 + 0.1833 9 CVR-R. However, there was no predictor
observed that defined the lag time.
Relationships between GE and postprandial glucose excursion
by GLP-1 RA administration
The baseline characteristics of the diabetes patients are listed in
Table 3. None of these showed positive results in the Schellong
test or a decreased CVR-R, suggesting the absence of diabetic
autonomic neuropathy. After GLP-1 RA administration, eight
participants with type 2 diabetes mellitus completed the study
with no adverse events, including gastrointestinal symptoms.
Their postprandial glucose levels at 120–180 min after 1 month
were significantly decreased (T = 120 min, P = 0.017;
T = 180 min, P = 0.043; Figure 2a).
Figure 2b shows the relationship between GE and PPGEs.
The increase in the blood glucose level from T0 min to T60 min
(DBG60-0 min) was significantly related to the GEC in the over-
all population (r2 = 0.7815, P < 0.001). In contrast, there was
no correlation between the magnitude of the postprandial rise
in blood glucose levels and the lag time, insulin secretion. The
relationships between the rate of change in various factors and
the rate of change in GEC by the administration of GLP-1 RAs
are provided in Figure 3. The rate of change was calculated as
follows: (1 – [the value at 1 month / before value]) 9 100 (%).
A positive correlation between the rates of change for GEC and
DBG60-0 min was observed (r
2 = 0.8170, P = 0.0021). However,
no significant relationships were observed between the rates of
change for GEC and the rates of change for HbA1c level, body-
weight and insulin secretion rate at 0 min by SUIT (SUIT0).
Comparison of the effects of short- and long-acting GLP-1
RAs on GE and postprandial glucose excursion
Principal component analysis was carried out to determine the
effects of GLP-1 RAs, and we found that, using the GEC as the
first main component (91.0%) and the stimulated insulin secre-
tion (stimulated SUIT60) as the second component (8.98%),
GLP-1 RAs can be categorized into two groups (Figure 3E).
One corresponds to short-acting GLP-1 RAs and the other to
long-acting GLP-1 RAs.
Table 2 | Multiple linear regression equation
Variable Coefficient (b) SE 95% CI P-value
Intercept 2.2706 0.2600 1.77–2.77 <0.001
CVR-R 0.1833 0.0549 0.07–0.30 0.0049
CI, confidence interval; CVR-R, coefficient of variation of R-R intervals; SE,
standard error.
Table 3 | Characteristics of the participants with type 2 diabetes by glucagon-like peptide-1 receptor agonist administration
Group 1 Group 2
n (male/female) 4 (2/2) 4 (3/1)
Age (years) 55.5 – 22.1 55.8 – 14.9
BMI (kg/m2) 32.0 – 4.1 26.9 – 4.4
Duration of diabetes (years) 18.0 – 20.8 13.3 – 7.70
Fasting plasma glucose (mg/dL) 162 – 57.2 152.5 – 37.6
HbA1c (%) 9.8 – 2.3 8.50 – 0.60
CPI/SUIT 1.01 – 0.76/26.8 – 23.4 1.61 – 0.60/45.0 – 22.3
Retinopathy: none 3 1
Simple 0 2
Preproliferative 1 (Stable) 1 (Stable)
Proliferative 0 0
Nephropathy: none 2 3
Microalbuminuria 2 0
Macroalbuminuria 0 1
Peripheral neuropathy (n) 3 4
GLP-1 RA
Short-acting 4 (Exenatide: 1, Lixisenatide: 3) 0
Long-acting 0 4 (Liraglutide: 4)
Data are presented the mean – standard deviation. BMI, body mass index; CPI, C-peptide immunoreactivity index; GLP-1 RA, glucagon-like peptide-
1 receptor agonist; HbA1c, glycated hemoglobin; SUIT, secretory units of islets in transplantation.
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Assessments of glucose excursion and insulin secretion, in
addition to PDR and CPDR, were carried out during the meal
test in each category (Figure 4). The GEC was significantly
declined after 1 week and 1 month, compared with before
treatment, indicating that short-acting GLP-1 RA use led to
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Figure 2 | (a) Changes in the gastric emptying values and glucose excursion in type 2 diabetes mellitus patients by the administration of glucagon-
like peptide-1 receptor agonists during three different stages. Gastric emptying coefficient (GEC), lag time and blood glucose profile (before, white
circles; after 1 week, black circles; after 1 month; black triangles). (b) Plots of the relationships among the changes in the gastric values, insulin
secretion and changes in the blood glucose levels from T0 min to T60 min during three different stages. GEC, lag time, insulin secretion rate at 0 min
by secretory units of islets in transplantation (SUIT0) and insulin secretion rate at 60 min by secretory units of islets in transplantation (SUIT60). The
Pearson correction coefficient (r2) and P-values were calculated as follows: GEC r2 = 0.7815, P < 0.001; lag time r2 = 0.0025, P = 0.4846; SUIT0 r2 =
0.005, P = 0.74; and SUIT60 r2 = 0.120, P = 0.09. DBG60-0 min, change in the blood glucose level from T0 min to T60 min.
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(range 1.64–2.39) and 2.20 (range 1.38–2.55) before, 1 week
after and 1 month after treatment, respectively (before vs
1 week after treatment, P = 0.0112; before vs 1 month after
treatment, P = 0.0122), whereas there was no change in the lag
time with short-acting GLP-1 RA treatment (Figure 4C). The
rate of change in the stimulated SUIT60 was increased. There-
fore, glucose elevations from T0 min to T60 min were suppressed
after 1 month (before vs 1 week after, P = 0.0131; before vs
1 month after, P = 0.0111, respectively; Figure 4d) and there
was a positive relationship between DBG60-0 min and the GEC
in the short-acting GLP-1 RA group (r2 = 0.6620, P = 0.0013;
Figure 5a).
In contrast, there was no significant difference in the GEC
before and after treatment with long-acting GLP-1 RAs; the
GEC values were 3.20 (range 2.98–3.90), 2.79 (range 2.46–3.95)
and 3.17 (range 2.75–3.79) before, 1 week after and 1 month
after treatment, respectively (before vs 1 week after, P = 0.22;


















–60 –40 –20 0 20
(%)
The rate of change in GEC The rate of change in GECThe rate of change in GEC
The rate of change in  A
1c
(a) (b) (c)(%)(%)
The rate of change  in BW










–60 –40 –20 0 20
The rate of change in GEC The rate of change in GEC
(d)







–60 –40 –20 0 20
Short-acting Long-acting






Figure 3 | Plots of the relationships among the rate of change in the blood glucose level from T0 min to T60 min, glycated hemoglobin,
bodyweight, insulin secretion and the rate of change in the gastric emptying coefficient (GEC) by the administration of glucagon-like peptide-1
receptor agonists. (a) Change in the blood glucose level from T0 min to T60 min (DBG60–0 min), (b) glycated hemoglobin, (c) bodyweight, (d) insulin
secretion rate at 0 min by secretory units of islets in transplantation (SUIT0) and (e) insulin secretion rate at 60 min by secretory units of islets in
transplantation (SUIT60). Short-acting, black square; long-acting, white square. BW, bodyweight.
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the stimulated SUIT30-180 was significantly increased only
after 1 week (P < 0.05); however, the glucose levels did not
change for 1 month (Figure 4d). The rate of change in the
stimulated SUIT60 was not increased, and there was no signifi-
cant decrease in DBG60–0 min for 1 month. Therefore, there was
no relationship between the magnitude of the postprandial rise
in blood glucose levels and the GEC in the long-acting GLP-1
RA group (Figure 5b).
DISCUSSION
In the present study, we evaluated the GE rates in healthy con-
trol participants and type 2 diabetes mellitus patients using
13CO2 excretion after the consumption of a combined solid
and liquid meal. We showed an association between GE and
PPGEs in type 2 diabetes mellitus patients after the administra-
tion of GLP-1 RAs. The BreathID system allows continuous
evaluation of GE and can serve as real-time breath analysis for
patients. To our knowledge, we are the first to show that GLP-
1 RAs reduce the GE rate in the early phase, using solid and
liquid meals, and control PPGE improvements in type 2 dia-
betes mellitus patients, using a continuous real-time breath test.
The poor correlation between intragastric distribution and
solid and liquid components has been reported in diabetes10.
The emptying of digestible solids is characterized by an initial
lag phase, after which, an emptying phase approximates a linear
pattern. In contrast, non-nutrient liquids empty from the stom-
ach in an overall mono-exponential pattern; that is, the GE of
non-nutrient liquids usually lacks an initial lag phase14, and the
initial emptying rate of liquids might be more rapid in diabetes
patients than those without the disease3, indicating that the
measurement of the GE of solids is more sensitive than that of
liquids in the diagnosis of gastroparesis24. In the present study,
the GEC, but not the lag time, could be predicted from the
CVR-R value, suggesting that the administration of a combina-
tion of solid and liquid meals and performance of continuous
breath tests can be useful in testing the GE ability in type 2
diabetes mellitus patients. Exogenous GLP-1 attenuates antral
motility, increases pyloric tone, stimulates duodenal motility
and relaxes the proximal stomach25. With the administration of
GLP-1 RAs, while the GEC was decreased, the lag time was
not affected. Therefore, the GE observed through the adminis-
tration of GLP-1 RA in the case of combined meals predomi-
nantly points to increased proximal and distal stomach
retention17.
GE is mainly controlled by the vagal nervous systems for the
regulation of the contraction and relaxation of gastric mus-
cles15,26. Vagal damage is an important cause of delayed GE;
delayed GE has been shown after vagotomy27. Intragastric meal
distribution might also be associated with diabetic autonomic
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Figure 4 | Time-course curves for gastric emptying and glucose excursion in short-acting glucagon-like peptide-1 receptor agonists and long-
acting glucagon-like peptide-1 receptor agonists during the three stages of examination (before, white circles; after 1 week, black circles; after
1 month; black triangles). (a) Percentage dose per hour of 13C recovered (PDR), (b) cumulative percentage dose (CPDR), (c) gastric emptying
coefficient (GEC) and (d) blood glucose. Data were analyzed by one-way analysis of variance for repeated measures; * and # indicate P < 0.05
(before vs after 1 week, and before vs after 1 month, respectively).
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evidence for the presence of autonomic neuropathy28. Although
we excluded patients with orthostatic hypotension, we observed
a significant relationship between autonomic nerve function
and GE, suggesting that autonomic nerve function plays an
important role in the pathogenesis of GE. Although the GEC is
a good indicator of GE, it is difficult to evaluate the GEC of
the GE index through daily medical examinations. The CVR-R
might be a reasonable surrogate marker for GE.
The reduction in the magnitude of PPGEs by GLP-1 RA
injection was significantly related to the magnitude of GE decel-
eration. The deceleration of GE had a stronger effect on the
reductions in the magnitude of PPGEs than stimulated post-
prandial insulin secretion. Exogenous GLP-1 has a direct rela-
tionship with postprandial glycemic response with the
deceleration of GE by GLP-1 in healthy participants15. Our
observation that GE can be controlled by the administration of
GLP-1 RA for type 2 diabetes mellitus patients, and that it is a
major determinant of postprandial glucose levels, is of interest.
The magnitude of the deceleration of GE by the administration
of GLP-1 RA can predict postprandial glucose elevations.
Although several drugs, in addition to GLP-1 RA, might modu-
late GE, whether these drugs affect postprandial glucose levels
should be further examined29,30.
Previous studies have shown that the glucose-lowering effects
of GLP-1 RA rely on the remaining b-cell function and that it
improves HbA1c31,32. As the present study was short term, the
effect of GLP-1 RA on blood glucose excursion was examined
by improvement of postprandial glucose rather than HbA1c.
We examined the relationship between DBG60–0 min and SUIT0
before and after administering GLP-1 RAs, and found that
there was no significant relationship between PPGE and insulin
secretion (short-acting: r2 = 0.0123, P = 0.7314; long-acting:
r2 = 0.0723, P = 0.3980). We suggested that GE rather than
insulin secretion of b-cells was more effective in the improve-
ment in postprandial blood glucose excursion after the adminis-
tration of GLP-1 RAs.
The present findings show that short-acting GLP-1 RA
administration led to the maintenance of decelerated GE for
1 month, and the reduction in the postprandial glucose level
was marked. Short-acting GLP-1 RA use can lead to continued
receptor stimulation without attenuation, and ensure the sus-
tained deceleration of GE in the early phase. Therefore, short-
acting GLP-1 RA administration might have a powerful impact
on the deceleration of GE. However, long-acting GLP-1 RA use
did not lead to the deceleration of GE, and did not reduce
postprandial glucose levels after 1 month of treatment, consis-
tent with the observation of tachyphylaxis after continuous
infusion of GLP-133. In the present study, GLP-1 RAs were cat-
egorized into two groups of the GEC and stimulated SUIT
index. The effects on the GEC and stimulated SUIT index
might lead to differences in the magnitude of postprandial
excursions between the short- and long-acting groups.
The present study had several limitations. First, the number
of patients was limited. When we administered GLP-1 RAs, we
examined only the mild complications associated with diabetes.
None of the patients had diabetic autonomic neuropathy. Sec-
ond, it is unclear whether GLP-1 RA use can affect the GEC
and lag time of GE and PPGEs in patients with gastroparesis.
Third, in the present study, the patients did not have gastroin-
testinal symptoms as a result of GLP-1 RA administration
(nausea, vomiting, diarrhea). The present findings did not show
if gastrointestinal symptoms were related to deceleration in GE.
In conclusion, we showed that there was no significant dif-
ference in the GE rates with the intake of a combined meal
between type 2 diabetes mellitus patients and healthy control
participants. However, the variations in the GE rates were lar-
ger in type 2 diabetes mellitus patients, and we found that
autonomic nerve function plays an important role in the patho-
genesis of GE. The difference in the effects on the deceleration
–50
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Figure 5 | Plots of the relationships between the change in blood
glucose levels from T0 min to T60 min (DBG60–0 min) and the gastric
emptying coefficient (GEC; before, white circles; after 1 week, black
circles; after 1 month; black triangles) in the (a) short-acting cases and
(b) long-acting cases. The Pearson correction coefficient (r2) and P-
values were calculated as follows: (a) r2 = 0.6620, P = 0.0013; and (b)
r2 = 0.1131, P = 0.2851.
ª 2019 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol. 11 No. 2 March 2020 397
O R I G I N A L A R T I C L E
http://wileyonlinelibrary.com/journal/jdi Gastric emptying in T2DM patients
of GE and stimulation of postprandial insulin secretion leads to
variations in postprandial glycemic excursion reductions
between short- and long-acting GLP-1 RAs. Through the evalu-
ation of GE, GLP-1 RAs can be selected appropriately, and the
effect of reduced PPGE in type 2 diabetes mellitus patients can
be predicted.
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